Tuesday, December 30, 2014 5:30:05 PM
ONVO has entered into an agreement with Cantor to sell up to $33MM of its shares on the open market (approx. 5MM shares at current prices.) This would be a dilution of approx. 6.25% if all shares were sold.
Prime reason for selling shares is payment of taxes on options currently held by officers if they elect under current terms. Secondary reason is for working capital.
"The Company intends to use discretion in initiating sales, if any, under the Sales Agreement. As previously disclosed, the Company granted
restricted stock units (“RSUs”) to certain of its executive officers in August 2012 in connection with becoming a publicly traded company.
These RSUs vest based on the executive officers’ achievement of performance milestones or the satisfaction of continued service requirements
through 2016. Under these awards, the executive officers can elect to pay the applicable federal and state withholding taxes due upon the
vesting of their RSUs by surrendering fully-vested shares to the Company. The Company then pays the tax withholdings directly to the Internal
Revenue Service (IRS) in an amount equal to the value of the shares surrendered by the executive officer. The Company expects, from time to
time, to make sales under the Sales Agreement equal to the number of shares that its executive officers have and may continue to surrender
through 2016 to pay for tax withholdings under their RSUs."
http://d1lge852tjjqow.cloudfront.net/NYSEAmex-ONVO/6ded38e2-9564-44b6-8ff0-779bf6d2c7ab.pdf?noexit=true
http://d1lge852tjjqow.cloudfront.net/NYSEAmex-ONVO/8f60c952-f162-4ee4-9d8e-675d967ba1fe.pdf?noexit=true
Prime reason for selling shares is payment of taxes on options currently held by officers if they elect under current terms. Secondary reason is for working capital.
"The Company intends to use discretion in initiating sales, if any, under the Sales Agreement. As previously disclosed, the Company granted
restricted stock units (“RSUs”) to certain of its executive officers in August 2012 in connection with becoming a publicly traded company.
These RSUs vest based on the executive officers’ achievement of performance milestones or the satisfaction of continued service requirements
through 2016. Under these awards, the executive officers can elect to pay the applicable federal and state withholding taxes due upon the
vesting of their RSUs by surrendering fully-vested shares to the Company. The Company then pays the tax withholdings directly to the Internal
Revenue Service (IRS) in an amount equal to the value of the shares surrendered by the executive officer. The Company expects, from time to
time, to make sales under the Sales Agreement equal to the number of shares that its executive officers have and may continue to surrender
through 2016 to pay for tax withholdings under their RSUs."
http://d1lge852tjjqow.cloudfront.net/NYSEAmex-ONVO/6ded38e2-9564-44b6-8ff0-779bf6d2c7ab.pdf?noexit=true
http://d1lge852tjjqow.cloudfront.net/NYSEAmex-ONVO/8f60c952-f162-4ee4-9d8e-675d967ba1fe.pdf?noexit=true
Recent VIVS News
- VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing • GlobeNewswire Inc. • 04/28/2026 12:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/06/2026 05:27:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:05:10 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 04/02/2026 08:00:55 PM
- VivoSim Announces Pricing of up to a $4 Million Public Offering • GlobeNewswire Inc. • 04/01/2026 12:05:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/31/2026 02:17:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 09:26:52 PM
- VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs • GlobeNewswire Inc. • 03/24/2026 12:05:00 PM
- VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales • GlobeNewswire Inc. • 03/03/2026 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:05:26 PM
- VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego • GlobeNewswire Inc. • 02/11/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:59:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:51:43 AM
- VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China • GlobeNewswire Inc. • 01/29/2026 09:05:00 PM
- VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer • GlobeNewswire Inc. • 01/06/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 09:05:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2025 11:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 09:08:13 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/03/2025 09:07:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/03/2025 09:06:32 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/28/2025 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2025 12:45:18 AM
